Larry Leon

430 total citations
14 papers, 316 citations indexed

About

Larry Leon is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Larry Leon has authored 14 papers receiving a total of 316 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 3 papers in Surgery. Recurrent topics in Larry Leon's work include Lung Cancer Treatments and Mutations (12 papers), Colorectal Cancer Treatments and Studies (10 papers) and Gastric Cancer Management and Outcomes (4 papers). Larry Leon is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Colorectal Cancer Treatments and Studies (10 papers) and Gastric Cancer Management and Outcomes (4 papers). Larry Leon collaborates with scholars based in United States, United Kingdom and Romania. Larry Leon's co-authors include Alan Sandler, David R. Spigel, Joan H. Schiller, Sebastien Hazard, Naiyer A. Rizvi, Luc Dirix, Peter Schmid, Laura Q.M. Chow, Jamie E. Chaft and Bo H. Chao and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology and Pancreas.

In The Last Decade

Larry Leon

14 papers receiving 309 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Larry Leon United States	8	258	232	41	36	28	14	316
K.H. Lee South Korea	9	322 1.2×	277 1.2×	52 1.3×	40 1.1×	18 0.6×	17	379
Rui Kitadai Japan	10	213 0.8×	161 0.7×	40 1.0×	35 1.0×	28 1.0×	27	296
T-E. Ciuleanu Romania	11	266 1.0×	240 1.0×	46 1.1×	57 1.6×	29 1.0×	47	345
David Vicente Baz Spain	10	173 0.7×	138 0.6×	29 0.7×	52 1.4×	17 0.6×	27	235
Giulia Grizzi Italy	12	262 1.0×	185 0.8×	70 1.7×	82 2.3×	41 1.5×	24	370
Yoshiro Nakahara Japan	12	282 1.1×	255 1.1×	54 1.3×	55 1.5×	23 0.8×	42	414
B. Killing Germany	7	288 1.1×	141 0.6×	45 1.1×	40 1.1×	57 2.0×	9	329
Ilze Bāra United States	9	260 1.0×	225 1.0×	38 0.9×	57 1.6×	37 1.3×	22	365
B.C. Cho South Korea	8	204 0.8×	232 1.0×	47 1.1×	90 2.5×	27 1.0×	33	280
Grant Toland United States	3	310 1.2×	194 0.8×	55 1.3×	22 0.6×	47 1.7×	5	347

Countries citing papers authored by Larry Leon

Since Specialization

Citations

This map shows the geographic impact of Larry Leon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Larry Leon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Larry Leon more than expected).

Fields of papers citing papers by Larry Leon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Larry Leon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Larry Leon. The network helps show where Larry Leon may publish in the future.

Co-authorship network of co-authors of Larry Leon

This figure shows the co-authorship network connecting the top 25 collaborators of Larry Leon. A scholar is included among the top collaborators of Larry Leon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Larry Leon. Larry Leon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Spigel, David R., Jamie E. Chaft, Scott Gettinger, et al.. (2018). FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC. Journal of Thoracic Oncology. 13(11). 1733–1742. 114 indexed citations

Hurwitz, Herbert I., John D. Hainsworth, Charles Swanton, et al.. (2016). Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: Early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors.. Journal of Clinical Oncology. 34(4_suppl). 653–653. 16 indexed citations

Leon, Larry, Michael P. Kosty, Mohammad Jahanzeb, et al.. (2016). Effectiveness of bevacizumab exposure beyond disease progression in patients with non–small‐cell lung cancer: analyses of the ARIES observational cohort study. Pharmacoepidemiology and Drug Safety. 25(5). 569–577. 3 indexed citations

Kosty, Michael P., Antoinette J. Wozniak, Mohammad Jahanzeb, et al.. (2015). Effectiveness and safety of post-induction phase bevacizumab treatment for patients with non-small-cell lung cancer: results from the ARIES observational cohort study. Targeted Oncology. 10(4). 509–516. 5 indexed citations

Langer, Corey J., Mark A. Socinski, Jyoti D. Patel, et al.. (2015). Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non–Small Cell Lung Cancer. American Journal of Clinical Oncology. 39(5). 441–447. 35 indexed citations

Osarogiagbon, Raymond U., Federico Cappuzzo, Tudor–Eliade Ciuleanu, Larry Leon, & Barbara Klughammer. (2015). Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials.. PubMed. 4(4). 465–74. 20 indexed citations

Burris, Howard A., Herbert I. Hurwitz, Edith A. Perez, et al.. (2015). MyPathway: An open-label phase IIa study of trastuzumab/pertuzumab, erlotinib, vemurafenib, and vismodegib in patients who have advanced solid tumors with mutations or gene expression abnormalities targeted by these agents.. Journal of Clinical Oncology. 33(15_suppl). TPS11111–TPS11111. 7 indexed citations

Langer, Corey J., Antoinette J. Wozniak, Mark A. Socinski, et al.. (2015). Does time to progression (TTP) influence post-progression survival (ppOS)?: Analyses from the PointBreak, ECOG 4599, and ARIES studies of bevacizumab in non–small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 33(15_suppl). e19019–e19019. 1 indexed citations

Lynch, Thomas J., David R. Spigel, Julie R. Brahmer, et al.. (2014). Safety and Effectiveness of Bevacizumab-Containing Treatment for Non–Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study. Journal of Thoracic Oncology. 9(9). 1332–1339. 44 indexed citations

10.

Osarogiagbon, Raymond U., Federico Cappuzzo, Tudor–Eliade Ciuleanu, & Larry Leon. (2013). Erlotinib after initial platinum-doublet chemotherapy in patients with epidermal growth factor receptor (EGFR) wild-type (WT) non-small cell lung cancer (NSCLC): Results of a combined patient-level analysis of the BR.21 and SATURN trials.. Journal of Clinical Oncology. 31(15_suppl). 8080–8080. 2 indexed citations

11.

Langer, Corey J., Mark A. Socinski, Jyoti D. Patel, et al.. (2013). Efficacy and safety of paclitaxel and carboplatin with bevacizumab for the first-line treatment of patients with nonsquamous non-small cell lung cancer (NSCLC): Analyses based on age in the phase III PointBreak and E4599 trials.. Journal of Clinical Oncology. 31(15_suppl). 8073–8073. 10 indexed citations

12.

López-Chávez, Ariel, Larry Leon, Joan H. Schiller, et al.. (2012). Bevacizumab Maintenance in Patients with Advanced Non–Small-Cell Lung Cancer, Clinical Patterns, and Outcomes in the Eastern Cooperative Oncology Group 4599 Study: Results of An Exploratory Analysis. Journal of Thoracic Oncology. 7(11). 1707–1712. 41 indexed citations

13.

Stepanski, Edward J., Carolina Reyes, Mark S. Walker, et al.. (2012). The Association of Rash Severity With Overall Survival. Pancreas. 42(1). 32–36. 15 indexed citations

14.

Pérez-Soler, Román, Larry Leon, & Slawomir Wojtowicz‐Praga. (2012). Cutaneous toxicity secondary to erlotinib therapy in patients with non-small cell lung cancer in the NCIC CTG BR.21 study: Time course and correlation with survival.. Journal of Clinical Oncology. 30(15_suppl). 7573–7573. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact